Atorvastatin Use in Patients with Hepatitis

Monitoring and Contraindications

For patients with hepatitis, more frequent monitoring of liver function tests is prudent, particularly during the initial months of therapy, as recommended by the American Gastroenterological Association 1
Atorvastatin should be discontinued in patients with immune checkpoint inhibitor-induced hepatitis of grade 2 or higher, as suggested by the American Gastroenterological Association 1, 2

When treating patients with hepatitis C who are on direct-acting antiviral therapy, potential drug interactions with atorvastatin should be considered, as noted by the European Association for the Study of the Liver 3, 4
For patients with HIV-hepatitis coinfection, caution should be used when prescribing statins with protease inhibitors and nonnucleoside reverse transcriptase inhibitors due to potential serious drug-drug interactions, as advised by the Infectious Diseases Society of America 5

In patients with hepatitis who are also taking immunosuppressants, the dose of atorvastatin should not exceed 10 mg daily without close monitoring of creatinine kinase and signs or symptoms of muscle-related toxicity, as recommended by the American Heart Association 6, 7

Assessing baseline liver function and severity of hepatitis is crucial before initiating atorvastatin therapy, as suggested by the American Gastroenterological Association 1
The American Gastroenterological Association recommends ruling out decompensated cirrhosis or acute liver failure before starting atorvastatin therapy 2
Checking for potential drug interactions with concurrent hepatitis treatments is essential, as noted by the European Association for the Study of the Liver 3
Starting with an appropriate dose based on cardiovascular risk and hepatic function is vital, as recommended by the American Heart Association 6
Monitoring liver enzymes more frequently, especially during initial therapy, is crucial, as suggested by the American Gastroenterological Association 2
Discontinuing atorvastatin if ALT/AST increase to >3x ULN with symptoms or if jaundice develops is recommended, as advised by the American Gastroenterological Association 2